NEXI NexImmune, Inc.

NexImmune is developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. Our AIM technology is designed to generate a targeted T cell-mediated immune response and is initially being developed as a cell therapy for the treatment of hematologic malignancies. AIM nanoparticles act as synthetic dendritic cells to deliver immune-specific signals to targeted T cells and can direct the activation or suppression of cell-mediated immunity. In cancer, AIM-expanded T cells have demonstrated best-in-class anti-tumor properties as characterized by in vitro analysis, including a unique combination of anti-tumor potency, antigen target-specific killing, and long-term T cell persistence. The modular design of the AIM platform enables rapid expansion across multiple therapeutic areas, with both cell therapy and injectable products.

$6.32
As of 12/03/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/12/2021
Outstanding shares:  22,711,247
Average volume:  40,320
Market cap:   $163,520,978
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    65344D109
ISIN:        US65344D1090
Sedol:      BNDC2M9
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.48
PS ratio:   0.00
Return on equity:   -67.18%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy